Article
Media matters: culture medium-dependent hypervariable phenotype of mesenchymal stromal cells.
Stem cell research & therapy - 12 Dec 2023
Fitzgerald Joan C, Shaw Georgina, Murphy J Mary, Barry Frank
Abstract excerpt
BACKGROUND: Despite a long history of investigation and sustained efforts in clinical testing, the number of market authorisations for mesenchymal stromal cell (MSC) therapies remains limited, with none approved by the United States Food and Drug Administration. Several barriers are impeding the clinical progression of MSC therapies, to the forefront of these is a lack of standardised manufacturing protocols...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
